Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (Nasdaq: TDAC) is a blank-check company targeting the healthcare and life sciences sector, with a particular focus on opportunities in translational medicine and biopharmaceutical development. The company filed a Form 10-Q with the Securities and Exchange Commission on August 14, 2025, under accession number 0001410578-25-001812, reflecting its continued reporting obligations as a public SPAC. The "translational development" mandate signals an intent to identify targets that bridge scientific discovery and commercial clinical application, a segment that has attracted sustained SPAC sponsor interest in recent years. For full filing history, sponsor details, deal timeline, and real-time status updates on TDAC, sign up for complete data access at SpacDesk.